KCT0000801Recruiting未知
A Comparison of LY2605541 versus Human Insulin NPH as Basal Insulin Treatment in Insulin-Naive Patients with Type 2 Diabetes Mellitus not Adequately Controlled with 2 or more Oral Antihyperglycemic Medications: An Open-Label,Randomized Study The IMAGINE 6 Study
Eli Lilly Korea0 sites80 target enrollmentStarted: TBDLast updated:
Conditions
Trial Snapshot
- Phase
- 未知
- Status
- Recruiting
- Sponsor
- Enrollment
- 80
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional Study
Eligibility Criteria
- Ages
- 18(Year) to o Limit (—)
- Sex
- All
Inclusion Criteria
- •Patients with T2DM who are 18 years or older,
- •treated with at least 2 OAMs for at least 3 months prior to the study and who are insulin naive and have a baseline
- •HbA1c of 7.0% to 11.0% as determined by the central laboratory at Visit 1 are eligible for this study.
Exclusion Criteria
- •should not have used insulin therapy in the past 2 years and should not have been treated with glucagon-like
- •peptide-1 (GLP-1) receptor agonist, rosiglitazone, pramlintide, or weight-loss medication within 3 months of Visit
- •1. Patients using DPP-IV inhibitors that are approved for use in combination with insulin are allowed to participate
- •in the study. Patients using pioglitazone may be allowed to participate depending on restrictions for use in
- •combination with insulin or metformin described in the local label. Patients should not have had any episodes of
- •severe hypoglycemia, diabetic ketoacidosis, or hyperosmolar state/coma within 6 months prior to Visit 1.
Investigators
Similar Trials
Active, not recruiting
Not Applicable
A 6-month study to compare a new long-acting insulin and Human Insulin NPH in Patients with type 2 diabetesMedDRA version: 14.1Level: LLTClassification code 10049746Term: Insulin-requiring type II diabetes mellitusSystem Organ Class: 100000004861Type 2 Diabetes MellitusEUCTR2012-003941-13-DEEli Lilly and Company630
Active, not recruiting
Phase 1
A 6-month study to compare a new long-acting insulin and Human Insulin NPH in Patients with type 2 diabetesMedDRA version: 16.0Level: LLTClassification code 10049746Term: Insulin-requiring type II diabetes mellitusSystem Organ Class: 100000004861Type 2 Diabetes MellitusEUCTR2012-003941-13-CZEli Lilly and Company630
Active, not recruiting
Not Applicable
A 6-month study to compare a new long-acting insulin and Human Insulin NPH in Patients with type 2 diabetesMedDRA version: 16.0Level: LLTClassification code 10049746Term: Insulin-requiring type II diabetes mellitusSystem Organ Class: 100000004861Type 2 Diabetes MellitusEUCTR2012-003941-13-PLEli Lilly and Company630
Active, not recruiting
Not Applicable
A 6-month study to compare a new long-acting insulin and Human Insulin NPH in Patients with type 2 diabetesMedDRA version: 15.1Level: LLTClassification code 10049746Term: Insulin-requiring type II diabetes mellitusSystem Organ Class: 100000004861Type 2 Diabetes MellitusEUCTR2012-003941-13-ESilly S.A.630
Active, not recruiting
Not Applicable
A 6-month study to compare a new long-acting insulin and Human Insulin NPH in Patients with type 2 diabetesType 2 Diabetes MellitusMedDRA version: 14.1Level: LLTClassification code 10049746Term: Insulin-requiring type II diabetes mellitusSystem Organ Class: 100000004861EUCTR2012-003941-13-HUEli Lilly and Company630